» Articles » PMID: 29081931

Atypical Clinical Presentation and Successful Treatment with Oral Cholic Acid of a Child with Defective Bile Acid Synthesis Due to a Novel Mutation in the Gene

Overview
Journal Pediatr Rep
Publisher MDPI
Specialty Pediatrics
Date 2017 Oct 31
PMID 29081931
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

We report definitive diagnosis and effective treatment with oral cholic acid in one Italian male child affected by 3β-hydroxy-Δ-C-steroid dehydrogenase (3β-HSD) deficiency. He presented with failure to thrive, hepatomegaly and multiple cystic images in kidneys; no biochemical evidence of cholestasis. Large amounts of bile acid metabolites was detected in urine by fast atom bombardment ionization mass spectrometry (FAB-MS). HSDH3B7 gene analysis identified one mutation in intron 4, at nucleotide 432, G>A substitution that has never been reported before.The replacement therapy with oral cholic acid started early after the diagnosis and is still ongoing. Three years later hepatomegaly is no longer evident, liver function is normal and the child is growing regularly. In our experience, clinical features of 3β-HSD deficiency can be very poor and even cholestasis can lack at diagnosis. Early replacement therapy with cholic acid is safe and leads to clinical and biochemical control of the disease.

Citing Articles

The clinical and biochemical effectiveness and safety of cholic acid treatment for bile acid synthesis defects: a systematic review.

Polak Y, van Dussen L, Kemper E, Vaz F, Klouwer F, Engelen M Orphanet J Rare Dis. 2024; 19(1):466.

PMID: 39702264 PMC: 11657003. DOI: 10.1186/s13023-024-03449-7.


Product Validation and Stability Testing of Pharmacy Compounded Cholic Acid Capsules for Dutch Patients with Rare Bile Acid Synthesis Defects.

Polak Y, Jacobs B, Bouwhuis N, Hollak C, Kroon M, Kemper E Pharmaceutics. 2023; 15(3).

PMID: 36986634 PMC: 10059964. DOI: 10.3390/pharmaceutics15030773.


Genetic spectrum and clinical characteristics of 3β-hydroxy-Δ-C-steroid oxidoreductase (HSD3B7) deficiency in China.

Zhao J, Setchell K, Gong Y, Sun Y, Zhang P, Heubi J Orphanet J Rare Dis. 2021; 16(1):417.

PMID: 34627351 PMC: 8501698. DOI: 10.1186/s13023-021-02041-7.


A recurrent ABCC2 p.G693R mutation resulting in loss of function of MRP2 and hyperbilirubinemia in Dubin-Johnson syndrome in China.

Wu L, Li Y, Song Y, Zhou D, Jia S, Xu A Orphanet J Rare Dis. 2020; 15(1):74.

PMID: 32183854 PMC: 7079413. DOI: 10.1186/s13023-020-1346-4.

References
1.
Cheng J, Jacquemin E, Gerhardt M, Nazer H, Cresteil D, Heubi J . Molecular genetics of 3beta-hydroxy-Delta5-C27-steroid oxidoreductase deficiency in 16 patients with loss of bile acid synthesis and liver disease. J Clin Endocrinol Metab. 2003; 88(4):1833-41. DOI: 10.1210/jc.2002-021580. View

2.
Rinawi F, Iancu T, Hartman C, Cohen H, Yarden-Bilavsky H, Rozenfeld Bar Lev M . Fat malabsorption due to bile acid synthesis defect. Isr Med Assoc J. 2015; 17(3):190-2. View

3.
Molho-Pessach V, Rios J, Xing C, Setchell K, Cohen J, Hobbs H . Homozygosity mapping identifies a bile acid biosynthetic defect in an adult with cirrhosis of unknown etiology. Hepatology. 2011; 55(4):1139-45. PMC: 3771532. DOI: 10.1002/hep.24781. View

4.
Jacquemin E, Setchell K, OConnell N, Estrada A, Maggiore G, Schmitz J . A new cause of progressive intrahepatic cholestasis: 3 beta-hydroxy-C27-steroid dehydrogenase/isomerase deficiency. J Pediatr. 1994; 125(3):379-84. DOI: 10.1016/s0022-3476(05)83280-9. View

5.
Song P, Zhang Y, Klaassen C . Dose-response of five bile acids on serum and liver bile Acid concentrations and hepatotoxicty in mice. Toxicol Sci. 2011; 123(2):359-67. PMC: 3179674. DOI: 10.1093/toxsci/kfr177. View